Solid Biosciences (SLDB) Q1 2025 earnings summary

Executive summary

• Advancing gene therapy candidates for rare neuromuscular and cardiac diseases, including SGT-003 (Duchenne), SGT-212 (Friedreich's ataxia), SGT-501 (CPVT), and SGT-601 (TNNT2 DCM).

• SGT-003 Phase 1/2 trial showed positive initial 90-day data with robust microdystrophin expression, improved biomarkers, and encouraging safety; no serious adverse events or acute liver injury.

• SGT-212 IND cleared by FDA for Friedreich's Ataxia; Phase 1b trial planned for 2H 2025.

• SGT-501 IND submission for CPVT anticipated in 1H 2025, following completion of GLP toxicology studies.

• Pipeline expansion supported by recent asset acquisitions, milestone-driven collaborations, and 19 partnerships for AAV-SLB101.

Financial highlights

• Net loss of $39.3 million for Q1 2025, up from $24.3 million in Q1 2024, driven by increased R&D and personnel costs.

• Research and development expenses rose 63.8% year-over-year to $30.9 million, mainly due to SGT-003 and SGT-212 program costs.

• General and administrative expenses increased to $9.1 million, reflecting higher personnel costs.

• Cash, cash equivalents, and available-for-sale securities totaled $306.9 million as of March 31, 2025, up from $148.9 million at December 31, 2024.

• No product revenue generated; company remains pre-commercial.

Outlook and guidance

• Current cash position expected to fund operations into the first half of 2027.

• Plans to dose ~20 participants in INSPIRE DUCHENNE trial by year-end 2025 and meet FDA in Q4 2025 to discuss accelerated pathways.

• SGT-212 Phase 1b trial for FA to begin in 2H 2025, enrolling both ambulatory and non-ambulatory adults.

• SGT-501 IND submission for CPVT expected in 1H 2025; SGT-601 IND submission anticipated in 2H 2026.

• Additional funding will be required beyond 2027 to sustain operations and advance pipeline.